文献速递血栓与止血贫血与红细胞疾病

获得性Glanzmann血小板无力症与血小板去唾液酸化相关

Acquired Glanzmann thrombasthenia associated with platelet desialylation.
PubMed 文献 · J Thromb Haemost · 2020-01-22

本文报告一例原发性免疫性血小板减少症(ITP)患者脾切除后血小板计数正常但仍出血,诊断为获得性Glanzmann血小板无力症(GT)。研究发现抗血小板抗体通过FcγRIIa诱导血小板去唾液酸化,加速肝内清除,神经氨酸酶抑制剂奥司他韦可减轻抗体介导的血小板破坏。

要点

  • ITP患者血小板计数与出血表现不符时需考虑获得性GT。
  • 抗αIIb β3抗体通过FcγRIIa诱导去唾液酸化导致血小板清除。
  • 神经氨酸酶抑制剂可能减少抗体介导的血小板破坏。

核心结论

  • 获得性GT由ITP相关抗αIIb β3抗体经FcγRIIa介导血小板去唾液酸化所致,不依赖血小板活化。
  • 神经氨酸酶抑制剂治疗可能预防抗αIIb β3抗体导致的血小板清除。

研究设计与样本

  • 病例报告:一例原发性ITP患者因类固醇不耐受行脾切除术后仍出血。
  • 实验室研究:血小板聚集试验、流式细胞术、MAIPA、CHO细胞表达αIIb β3或GP Ib/IX。
  • 动物实验:非肥胖糖尿病/重症联合免疫缺陷(NOD/SCID)ITP小鼠模型。

主要发现

  • 患者血小板聚集试验除利托菌素外所有激动剂均异常。
  • 流式细胞术显示抗血小板抗体剂量依赖性抑制纤维蛋白原和PAC-1结合,诱导神经氨酸酶-1表达及供者血小板去唾液酸化。
  • 间接MAIPA证实抗体仅针对αIIb β3,CHO细胞表达人αIIb β3可结合而GP Ib/IX不结合。
  • 血浆吸附于Ib/IX CHO细胞及IgG组分均观察到去唾液酸化及神经氨酸酶表达。
  • 抗FcγRIIa抗体可抑制去唾液酸化;患者IgG使小鼠供者血小板在肝内快速清除,奥司他韦显著减少抗体诱导的血小板破坏。

临床怎么用

  • 对ITP患者血小板计数正常但仍出血,应评估获得性GT可能。
  • 可考虑检测抗αIIb β3抗体及血小板去唾液酸化。
  • 神经氨酸酶抑制剂(如奥司他韦)可能作为减少抗体介导血小板清除的治疗选择。

局限性

  • 为单例病例报告,结论需更大样本验证。
  • 动物模型结果不能直接外推至人类。
  • 奥司他韦的疗效尚未在临床试验中评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The notable discrepancy between platelet count and bleeding manifestations in immune thrombocytopenia (ITP) patients with acquired Glanzmann thrombasthenia (GT) has been described. OBJECTIVES: We aimed to examine the mechanisms responsible for thrombocytopenia and the bleeding phenotype in a patient with acquired GT. PATIENT, METHODS, AND RESULTS: A patient with primary ITP underwent splenectomy due to steroid intolerance. Despite platelet count normalization, bleeding continued. Platelet aggregometry was abnormal with all agonists except for ristocetin. Flow cytometry demonstrated the presence of antiplatelet antibody, which caused dose-dependent inhibition of fibrinogen and PAC-1 binding, induction of neuraminidase-1 expression as well as platelet desialylation in donor platelets. Indirect monoclonal antibody immobilization of platelet specific antigen assay (MAIPA) confirmed specificity to αIIb β3 only, corroborated by binding on Chinese hamster ovary (CHO) cells expressing human glycoprotein αIIb β3 but not GP Ib/IX. Both desialylation and neuraminidase expression were observed with plasma adsorbed on Ib/IX CHO cells and with the immunoglobulin G (IgG) fraction. Desialylation was inhibited in the presence of anti-Fc-gamma receptor IIa (FcγRIIa) antibody. A nonobese diabetic/severe combined immunodeficient ITP murine model was established, which showed rapid hepatic donor platelet clearance in the presence of patient IgG. Treatment of mice with the neuraminidase inhibitor oseltamivir significantly reduced antibody-induced platelet destruction. CONCLUSIONS: We report the first case of a patient with acquired GT due to ITP with FcγRIIa mediated platelet desialylation, independent of platelet activation. Treatment with neuraminidase inhibitor may prevent platelet clearance by anti-αIIb β3 antibodies.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Zheng SS, Perdomo JS, Leung HHL, et al. Acquired Glanzmann thrombasthenia associated with platelet desialylation. J Thromb Haemost. 2020. PMID: 31869497. doi:10.1111/jth.14722

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。